CFO
SMMT icon

CVA Family Office’s Summit Therapeutics SMMT Stock Holding History

CVA Family Office’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583 Hold
40
– – ﹤0.01% 1715
2026
Q1 		$758 Hold
40
– – ﹤0.01% 1693
2025
Q4 		$700 Hold
40
– – ﹤0.01% 1157
2025
Q3 		$826 Hold
40
– – ﹤0.01% 1156
2025
Q2 		$851 Buy
+40
New +$912 ﹤0.01% 1119

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CVA Family Office's SMMT Position: Q2 2026 in Review

CVA Family Office held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 40 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

CVA Family Office first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $851 in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • CVA Family Office held 40 shares of Summit Therapeutics worth $583 as of Q2 2026.
  • CVA Family Office left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1715 holding.
  • CVA Family Office first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • CVA Family Office's Summit Therapeutics position peaked at $851 in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.